Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: Results of the EPIC study

Leukemia

Volumn 21, Issue 11, 2007, Pages 2287-2295

  Rojas, J M ^a   Knight, K ^a   Wang, L ^a   Clark, R E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; EPITOPE; IMATINIB; INTERFERON; PEPTIDE DERIVATIVE; PROTEIN PADRE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANAPHYLAXIS; ARTICLE; BONE MARROW CELL; CANCER CONTROL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; FACE EDEMA; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNIZATION; MALE; MYALGIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TACHYCARDIA; TREATMENT DURATION;

EID: 35449008469     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404858     Document Type: Article

References (26)

1. Clark RE, Christmas SE. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. Leuk Lymphoma 2001; 42: 871-880.
2. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680-2684.
3. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukaemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
4. Posthuma EF, van Bergen CA, Kester MG, cle Paus RA, van Veelen PA, de Ru AH et al. Proteosomal degradation of BCR/ABL protein can generate an HLA-A301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. Haematologica 2004; 89: 1062-1071.
5. Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia,patients and healthy subjects. Haematologica 2005; 90 1315-1323.
6. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogerfous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892-2900.
7. Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and adoptive cellular immunotherapy. J. Immunol 2005; 174: 8210-8218.
8. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1: 751-761.
9. Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appel la E et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res 1998; 18: 79-92.
10. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T et al. Detection of T helper responses, but not of human papillornavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000; 23: 255-266.
11. Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett 2004; 92: 259-268.
12. Benrhohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopepticle without adjuvant induces systemic immune responses. Immunology 2002; 106: 113-121.
13. UyttenhoveC, Arendse B, StroobantV, Brombacher F, Van Snickj. Dévelopment of an anti-IL-12 p40 auto-vaccine: Protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol 2004; 34: 3572-3581.
14. Ghochikyan A, Mkrtichyan M, Petrushina 1, Movsesyan N, Karapetyan A, Cribbs DH et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 2006; 24: 2275-2282.
15. Jäger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jäger D et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996; 67: 54-62.
16. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug 1, Søoreide O et a̧l. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarci noma. Int J Cancer 2001; 92: 441-450.
17. McArdle SE, Ali SA, Li G, Mian S, Rees RC. Phenotypic and functional differences of dendritic cells generated,under different in vitro conditions. Methods Mol Med 2003; 81: 359-375.
18. Fonteneau JF, Larsson M, Somersan S, Sanders C, Munz C, Kwok WW et al. Generation of high quaritities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using pepticle pulsed mature dendritic cells. J Immunol Methods 2001; 258: 111-126.
19. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid lelukaemi.,Br I Haematol 2002; 118: 771-777.
20. Hughes TP,.Deininger MW, Hochhaus A, Branford-S,,RadicKJP, Kaecla J et al. Monitoring CML patients -responding to treatment with tyrosine kinase inhibitors: Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
21. Broughton CM, Sherrington P, Pender N, Tidd DM, Clark RE. Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. Genes Chromosomes Cancer 1997; 18: 292-298.
22. Cathcart K, Pinilla-lbarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-1042.
23. Bocchia M, Gentili S, Abruzzese E, Fanelli A, luliano, Tabilio A et al. Effect df a p2l 0 multipeptide vaccine associated 'with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005; 365: 657-662.
24. Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: Does it really matter? Leuk Lymphoma 2006; 47: 1-7.
25. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270.
26. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539.